Monitoring Minimal Residual Disease（MRD）in Pediatric B-acute Lymphoblastic Leukemia

Launched by SUN YAT-SEN UNIVERSITY · Jul 25, 2021

Keywords

ClinConnect Summary

This clinical trial is studying a new method to detect minimal residual disease (MRD) in children with B-acute lymphoblastic leukemia (B-ALL), a type of blood cancer. The researchers want to see how well a technique called next-generation sequencing (NGS), which looks at specific genetic changes, works compared to a traditional method called flow cytometry (FCM). The goal is to identify any remaining cancer cells after treatment early on, which could help doctors predict if the cancer might come back and allow for timely interventions to improve survival rates.

To participate in this trial, children must be 18 years old or younger and newly diagnosed with B-ALL, meaning they haven't received any treatment yet. Families will need to give their consent for their child to join the study. Participants can expect close monitoring and testing to help understand how well these methods work in tracking the disease. It's important to note that children with certain health issues, like other cancers or serious infections, may not be eligible to participate in this study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age≤18 years.
• • 2. Newly diagnosed B-ALL.
• • 3. No previous treatment.
• • 4. Signed informed consent in keeping with the policies of the hospital.
• Exclusion Criteria:
• • 1. History of other malignancies, except in situ carcinoma or malignancy treated with curative intent.
• • 2. Patients with active or uncontrollable infections such as hepatitis B, hepatitis C or HIV infection.
• • 3. Patients with uncontrolled autoimmune diseases or immune defects. Other protocol-defined Inclusion/Exclusion may apply.